<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02496377</url>
  </required_header>
  <id_info>
    <org_study_id>9408</org_study_id>
    <secondary_id>2014-A00642-45</secondary_id>
    <nct_id>NCT02496377</nct_id>
  </id_info>
  <brief_title>Cross Iron (Comparative Randomized Oral Versus Systemic IRON)</brief_title>
  <acronym>Cross Iron</acronym>
  <official_title>Comparison of Preoperative Haemoglobin Level After Administration of Epoetin Alfa Associated With an Oral Versus Intravenous Iron Supplementation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients were recruited at the scheduled preoperative visit for hip or knee arthroplasty. If
      the haemoglobin (Hb) level was below 13 g/dl with no contraindication to iron supplementation
      the patients were randomized to the oral or intravenous (IV) group. The oral group received
      160 mg ferrous glycine sulfate daily during the month prior surgery, associated with 3
      epoetin alpha (EPO) injections (40 000 IU subcutaneous on day - 21, day - 14 and day-7). The
      IV group received ferric carboxymaltose 1000 mg IV in 15 minutes one month before surgery,
      associated with 3 EPO injections. Primary efficacy endpoint was the change in Hb level from
      the day of the preoperative visit to the day before surgery (day-1). Secondary endpoints
      comprised the Hb level on day 3 and 5 after surgery, allogenic transfusion during and after
      surgery, and the change in iron indices from the day of the preoperative visit to day - 1.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2014</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">February 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compare Hb level after treatment with EPO associated with iron treatment by oral or intravenous route</measure>
    <time_frame>the day before surgery (day - 1)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hb level</measure>
    <time_frame>before iron treatment, then the day before surgery (day - 1) based on reference iron balance</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of red blood cells</measure>
    <time_frame>during surgery and 3 days after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the change in iron indices</measure>
    <time_frame>before iron treatment and after iron treatment the day before surgery (day - 1)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Allogenic Transfusion</condition>
  <condition>Perioperative Anaemia</condition>
  <condition>Knee Arthroplasty</condition>
  <condition>Hip Arthroplasty</condition>
  <arm_group>
    <arm_group_label>Group 1: Per Os Tardyferon</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>EPO associated with Iron per os tardyferon before surgery. The oral group received 160 mg ferrous glycine sulfate daily during the month prior surgery, associated with 3 epoetin alpha (EPO) injections (40 000 IU subcutaneous on day - 21, day - 14 and day-7).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: IV Ferinject</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EPO associated with Iron per IV Ferinject before surgery. The IV group received ferric carboxymaltose 1000 mg IV in 15 minutes one month before surgery, associated with 3 EPO injections.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ferrous glycine sulfate Tardyferon</intervention_name>
    <arm_group_label>Group 1: Per Os Tardyferon</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epoetin Alfa</intervention_name>
    <arm_group_label>Group 1: Per Os Tardyferon</arm_group_label>
    <arm_group_label>Group 2: IV Ferinject</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ferric carboxymaltose Ferinject</intervention_name>
    <arm_group_label>Group 2: IV Ferinject</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  unilateral prothetic orthopaedic surgery scheduled

          -  age &gt; 18

          -  weight &gt; 50 kg

          -  hemoglobin rate: 10 g/dl ≤ Hb &lt;13 g/dl

        Exclusion criteria:

          -  bilateral arthroplasty

          -  EPO contraindication

          -  generalized infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe BIBOULET, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Montpellier University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Philippe BIBOULET, MD, PhD</last_name>
    <phone>04 67 33 82 56</phone>
    <phone_ext>0033</phone_ext>
    <email>P-BIBOULET@CHU-MONTPELLIER.FR</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hôpital Lapeyronie - Département Anesthésie Réanimation A</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe BIBOULET, MD, PhD</last_name>
      <phone>04 67 33 82 56</phone>
      <phone_ext>0033</phone_ext>
      <email>P-BIBOULET@CHU-MONTPELLIER.FR</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 19, 2015</study_first_submitted>
  <study_first_submitted_qc>July 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2015</study_first_posted>
  <last_update_submitted>July 9, 2015</last_update_submitted>
  <last_update_submitted_qc>July 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anaemia</keyword>
  <keyword>Iron deficiency</keyword>
  <keyword>Ferric carboxymaltose</keyword>
  <keyword>Patient blood management</keyword>
  <keyword>Hip arthroplasty</keyword>
  <keyword>Knee arthroplasty</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iron</mesh_term>
    <mesh_term>Epoetin Alfa</mesh_term>
    <mesh_term>Ferric Compounds</mesh_term>
    <mesh_term>Glycine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

